Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NRIX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNurix reports 83% response rate for blood cancer drug bexobrutideg in heavily pre-treated patients
Filed June 11, 2026 · Period ending June 11, 2026 · ~1 min read
Key Changes
-
high
Phase 1 trial showed 83% objective response rate in relapsed/refractory CLL/SLL patients with median 4 prior therapies, including 38% with BTK resistance mutations. Median progression-free survival reached 22.1 months.
Item 7.01: Clinical Data verify on EDGAR → -
high
In earlier-line patients previously treated with BTK inhibitors but not BCL-2 inhibitors, response rate was 92.9% with 18 of 19 patients remaining on treatment at data cutoff.
Item 7.01: Cohort 5 verify on EDGAR → -
high
In BTK inhibitor-naïve patients including 10 treatment-naïve patients, response rate was 84.2% with 19 of 20 patients still on treatment, suggesting potential for first-line use.
Item 7.01: Cohort 15 verify on EDGAR → -
high
Safety profile across 142 patients showed no dose-limiting toxicities at 600mg dose. Three fatal adverse events occurred but were deemed unrelated to treatment. Common side effects included purpura, neutropenia, and fatigue.
Item 7.01: Safety Data verify on EDGAR → -
medium
Data presented at European Hematology Association Congress 2026 for bexobrutideg (NX-5948), a novel BTK degrader targeting blood cancers resistant to existing therapies.
Item 7.01: EHA2026 verify on EDGAR →
Summary
Nurix Therapeutics disclosed promising Phase 1 clinical trial results for bexobrutideg, an experimental drug for chronic lymphocytic leukemia and small lymphocytic lymphoma. The data shows the drug achieved an 83% response rate in heavily pre-treated patients who had failed a median of four prior therapies, with many harboring resistance mutations that make treatment difficult.
Notably, the drug demonstrated activity even in patients with BTK resistance mutations, a major challenge with existing therapies. Retail investors should care because these results suggest bexobrutideg could address a significant unmet need in blood cancer treatment, particularly for patients who have exhausted other options.
The drug also showed strong early results in less heavily treated patients and even treatment-naïve patients, potentially expanding its market opportunity beyond just relapsed/refractory disease. The safety profile appears manageable with no dose-limiting toxicities. Watch for the company's next steps toward pivotal trials and regulatory discussions with the FDA. The median progression-free survival of 22.1 months in heavily pre-treated patients is encouraging, but longer follow-up data and head-to-head comparisons with existing therapies will be critical to assess commercial viability.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Nurix announced updated Phase 1a/1b clinical data for BTK degrader bexobrutideg in relapsed/refractory CLL and SLL at EHA2026.
Added in current filing · verify on EDGAR →
On June 11, 2026, Nurix Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation at the European Hematology Association Congress (“EHA2026”) of updated clinical data from from the Phase 1a/1b study of the Company’s novel Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The company disclosed updated clinical trial results for its experimental cancer drug bexobrutideg, a BTK degrader being tested in blood cancer patients who have relapsed or not responded to prior treatments. The data was presented at a major European hematology conference. This is a Regulation FD disclosure, meaning the information is being shared publicly to comply with fair disclosure rules.
Event · Item 8.01 — Other Events
Nurix announced updated Phase 1 clinical trial data for bexobrutideg (NX-5948) showing 83% response rate in heavily pre-treated CLL/SLL patients.
Added in current filing · verify on EDGAR →
The updated Phase 1a data included 48 patients with relapsed or refractory CLL/SLL treated at starting dose levels ranging from 50 mg to 600 mg once daily, with a median follow-up of 22.4 months. Among the 47 response-evaluable patients, the objective response rate (ORR) was 83.0%, including two patients (4.3%) with a complete response, one patient (2.1%) with nodal partial response, and 36 patients (76.6%) with partial response. Six patients (12.8%) showed stable disease and two patients (4.3%) experienced progressive disease. Median progression-free survival was 22.1 months (95% Confidence Interval: 14.0 months to Not Reached).
In heavily pre-treated patients (median 4 prior therapies), bexobrutideg achieved an 83% objective response rate with median progression-free survival of 22.1 months after 22.4 months median follow-up. This represents strong efficacy in a difficult-to-treat population where many patients had resistance mutations and poor prognostic features.
Added in current filing · verify on EDGAR →
Cohort 5 enrolled 19 patients, 18 of whom remained on treatment as of the data cutoff. Among the 14 patients evaluable for response, the ORR was 92.9% with a median follow-up of 5.2 months.
In BTK inhibitor-treated but BCL-2 inhibitor-naïve patients, bexobrutideg showed a 92.9% response rate with 18 of 19 patients still on treatment at data cutoff. This demonstrates strong activity in an earlier-line treatment setting with high treatment retention.
Added in current filing · verify on EDGAR →
Cohort 15 enrolled 20 patients, including 10 treatment-naïve patients, 19 of whom remained on treatment as of the data cutoff. Among the 19 patients evaluable for response, the ORR was 84.2% with a median follow-up of 4.9 months.
In BTK inhibitor-naïve patients including 10 treatment-naïve patients, bexobrutideg achieved an 84.2% response rate with 19 of 20 patients remaining on treatment. This early data suggests the drug may be effective as a first-line therapy, potentially expanding its market opportunity beyond relapsed/refractory disease.
Added in current filing · verify on EDGAR →
The Phase 1a population had received a median of four prior lines of therapy (range = 2-12), including prior BTK inhibitors (97.9%), prior BCL2 inhibitors (83.3%) and prior non-covalent BTK inhibitors (27.1%). At baseline, many patients had mutations associated with BTK inhibitor resistance, including mutations in BTK (38.3%) and PLCG2 (14.9%). Poor prognostic features were common, including TP53 mutations (44.7%). Five patients (10.4%) in the Phase 1a population had central nervous system (CNS) involvement at baseline.
The Phase 1a patient population was heavily pre-treated with a median of 4 prior therapies, and 38.3% had BTK resistance mutations while 44.7% had TP53 mutations indicating poor prognosis. The strong efficacy results despite this challenging patient profile suggests bexobrutideg may address significant unmet medical need in resistant disease.
Event · Item 9.01 — Financial Statements and Exhibits
Nurix Therapeutics filed an 8-K attaching a press release dated June 11, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
99.1 Nurix Therapeutics, Inc. Press Release dated June 11, 2026
The 8-K references an attached press release dated June 11, 2026. The filing body itself contains no substantive disclosure; the press release content is not included in the provided text, so the nature of the announcement cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 11, 2026 · How we verify